No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PROK ProKidney
- 2.680
- -0.240-8.22%
Close Jun 18 16:00 ET
- 2.682
- +0.002+0.06%
Post 19:34 ET
320.36MMarket Cap-4701P/E (TTM)
3.000High2.661Low405.29KVolume2.960Open2.920Pre Close1.13MTurnover0.49%Turnover RatioLossP/E (Static)119.54MShares13.51052wk High-0.29P/B221.84MFloat Cap1.12052wk Low--Dividend TTM82.78MShs Float14.190Historical High--Div YieldTTM11.61%Amplitude1.120Historical Low2.787Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
ProKidney Closes Public, Registered Direct Offerings
ProKidney (PROK) said Monday that it has closed a public offering and concurrent registered direct offering. The biotech firm said it sold 46,886,452 class A shares in the public offering at $2.42 eac
Express News | ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
ProKidney Surges 18% Following Pricing of Upsized $130M Stock Offering
Express News | ProKidney Shares Down 1.7% Premarket After Co Announces Pricing of Upsized Public Offering
ProKidney Prices Upsized $130 Million Stock Offering
ProKidney (PROK) said late Tuesday it priced a $130 million underwritten public offering and a concurrent registered direct offering of about 53.7 million of its class A ordinary shares at $2.42 per s
ProKidney Plans to Use Proceeds for Clinical Trial Costs, R&D, Continued Investment, General Corporate Purposes >PROK
ProKidney Plans to Use Proceeds for Clinical Trial Costs, R&D, Continued Investment, General Corporate Purposes >PROK
Comments
$ProKidney(PROK.US$ ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
$ProKidney(PROK.US$
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2
$ProKidney(PROK.US$ ProKidney Announces Proposed $125 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering
$ProKidney(PROK.US$ Reuters
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg